ИССЛЕДОВАНИЕ ЭФФЕКТИВНОСТИ ИНДУКЦИИ ЦИТОТОКСИЧЕСКОГО ИММУННОГО ОТВЕТА МОНОНУКЛЕАРНЫМИ КЛЕТКАМИ С ПОМОЩЬЮ ДЕНДРИТНЫХ КЛЕТОК, ТРАНСФЕЦИРОВАННЫХ ПОЛИЭПИТОПНЫМИ КОНСТРУКЦИЯМИ HER2/ERBB2

This study describes a design of genetic constructs encoding either non-specific, or HLA-A *0201-specific polyepitopic immunogens containing antigenic determinants for HER2 protein. We have shown that transfection of mature dendritic cells by polyepitopic constructs with magnetic nanoparticles lead to effective in vitro stimulation of cytotoxic immune response of mononuclear cell populations obtained from HLA-A0201-positive healthy donors/ This cytotoxic action was assessed in vitro, as lethal effects upon HLA-A0201/HER2 double positive MCF-7 tumor cells, and expression of perforin granules.

1. Антонец Д.В., Максютов А.З. TEpredict: программное обеспечение для предсказания Т-клеточных эпитопов // Молекулярная биология. 2010. Т. 44, № 1. С. 130-139. [Antonets D.V., Maksyutov A.Z. Epredict: programmnoe obespechenie dlya predskazaniya T-kletochnykh epitopov [TEpredict: software for T-cell epitope prediction]. Molekulyarnaya biologiya = Molecular Biology, 2010, Vol. 44, no. 1, pp. 130-139].

2. Состояние онкологической помощи населению России в 2011 году / Под ред. В.И. Чиссова, В.В. Старинского, Г.В. Петровой. – М.: ФГБУ «МНИОИ им. П.А. Герцена» Минздравсоцразвития России, 2012. 240 с. [Sostoyanie onkologicheskoy pomoshchi naseleniyu Rossii v 2011 godu / Pod red. V.I. Chissova, V.V. Starinskogo, G.V. Petrovoy [Condition cancer care in Russia in 2011. Eds.: Chissov V.I., Starinskij V.V., Petrova G.V]. Moscow: FGBU «MNIOI im. P.A. Gercena» Minzdravsocrazvitija Rossii, 2012. 240 p].

3. Baxevanis C.N., Sotiriadou N.N., Gritzapis A.D., Sotiropoulou P.A., Perez S.A., Cacoullos N.T., Papamichail M. Immunogenic HER-2/neu peptides as tumor vaccines Cancer Immunol. Immunother., 2006, Vol. 55, no. 1, pp. 85-95.

4. Benavides L.C., Gates J.D., Carmichael M.G., Patil R., Holmes J.P., Hueman M.T., Mittendorf E.A., Craig D., Stojadinovic A., Ponniah S., Peoples G.E. The impact of HER2/neu expression level on response to the E75 vaccine: from U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin Cancer Res., 2009, Vol. 15, no. 8, pp. 2895-2904.

5. Bendtsen J.D., Nielsen H., von Heijne G., Brunak S. Improved prediction of signal peptides: SignalP 3.0. J. Mol. Biol., 2004, Vol. 340, no. 4, pp. 783-795.

6. Bonehill A., Heirman C., Tuyaerts S., Michiels A., Breckpot K., Brasseur F., Zhang Y., Van Der Bruggen P., Thielemans K. Messenger RNA-electroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and class II molecules. J. Immunol., 2004, Vol. 172, no. 11, pp. 6649-6657.

7. Bonini C., Lee S.P., Riddell S.R., Greenberg P.D. Targeting antigen in mature dendritic cells for simultaneous stimulation of CD4+ and CD8+ T cells. J. Immunol., 2001, Vol. 166, no. 8, pp. 5250-5257.

8. Fassnacht M., Lee J., Milazzo C., Boczkowski D., Su Z., Nair S., Gilboa E. Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy. Clin Cancer Res., 2005, Vol. 11, no. 15, pp. 5566-5571.

9. Foley J., Nickerson N.K., Nam S., Allen K.T., Gilmore J.L., Nephew K.P., Riese D.J. EGFR signaling in breast cancer: bad to the bone. Semin Cell Dev Biol., 2010, Vol. 21, no. 9, pp. 951-960.

10. Gattinoni L., Powell D.J., Rosenberg S.A., Restifo N.P. Adoptive immunotherapy for cancer: building on success. Nat. Rev. Immunol., 2006, Vol. 6, no. 5, pp. 383-393.

11. Hsieh C.S., deRoos P., Honey K., Beers C., Rudensky A.Y. A role for cathepsin L and cathepsin S in peptide generation for MHC class II presentation. J. Immunol., 2002, Vol. 168, no. 6, pp. 2618-2625.

12. Jarnjak-Jankovic S., Hammerstad H., Saeb e-Larssen S., Kvalheim G., Gaudernack G. A full scale comparative study of methods for generation of functional Dendritic cells for use as cancer vaccines. BMC Cancer, 2007, Vol. 7, p. 119.

13. Kamangar F., Dores G.M., Anderson W.F. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J. Clin. Oncol., 2006, Vol. 24, no. 14, pp. 2137-2150.

14. Kato M., Neil T.K., Fearnley D.B., McLellan A.D., Vuckovic S., Hart D.N. Expression of multilectin receptors and comparative FITC-dextran uptake by human dendritic cell. Int. Immunol., 2000, Vol. 11, pp. 1511- 1519.

15. Livingston B.D, Newman M., Crimi C., McKinney D., Chesnut R., Sette A. Optimization of epitope processing enhances immunogenicity of multiepitope DNA vaccines. Vaccine, 2001, Vol. 19, no. 32, pp. 4652-4660.

16. Lundegaard C., Lamberth K., Harndahl M., Buus S., Lund O., Nielsen M. NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11. Nucleic Acids Res., 2008, Vol. 36, pp. 509-512.

17. Obermaier B., Dauer M., Herten J., Schad K., Endres S., Eigler A. Development of a new protocol for 2-day generation of mature dendritic cells from human monocytes. Biol Proced Online, 2003, Vol. 5, pp. 197-203.

18. Peters B., Bulik S., Tampe R., Van Endert P.M., Holzh tter H.G. Identifying MHC class I epitopes by predicting the TAP transport efficiency of epitope precursors. J. Immunol., 2003, Vol. 171, no. 4, pp. 1741-1749.

19. Ross J.S., Slodkowska E.A., Symmans W.F., Pusztai L., Ravdin P.M., Hortobagyi G.N. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist., 2009, Vol. 14, no. 4, pp. 320-368.

20. Rufer N., Br mmendorf T.H., Kolvraa S., Bischoff C., Christensen K., Wadsworth L., Schulzer M., Lansdorp P.M. Telomere fluorescence measurements in granulocytes and T lymphocyte subsets point to a high turnover of hematopoietic stem cells and memory T cells in early childhood. J. Exp. Med., 1999, Vol.1 90, no. 2, pp. 157-167.

21. Singh H., Raghava G.P. ProPred: prediction of HLA-DR binding sites. Bioinformatics., 2001, Vol. 17, no. 12, pp. 1236-1237.

22. Tanaka F., Yamaguchi H., Haraguchi N., Mashino K., Ohta M., Inoue H., Mori M. Efficient induction of specific cytotoxic T lymphocytes to tumor rejection peptide using functional matured 2 day-cultured dendritic cells derived from human monocytes. Int. J. Oncol., 2006, Vol. 29, no. 5, pp. 1263-1268.

23. Toes R.E., Nussbaum A.K., Degermann S., Schirle M., Emmerich N.P., Kraft M., Laplace C., Zwinderman A., Dick T.P., M ller J., Sch nfisch B., Schmid C., Fehling H.J., Stevanovic S., Rammensee H.G., Schild H. Discrete cleavage motifs of constitutive and immunoproteasomes revealed by quantitative analysis of cleavage products. J. Exp. Med., 2001, Vol. 194, no. 1, pp. 1-12.

24. Tuyaerts S., Aerts J.L, Corthals J., Neyns B., Heirman C., Breckpot K., Thielemans K., Bonehill A. Current approaches in dendritic cell generation and future implications for cancer immunotherapy. Cancer Immunol Immunother., 2007, Vol. 56, no. 10, pp. 1513-1537.

25. Zhang T., Maekawa Y., Hanba J., Dainichi T., Nashed B.F., Hisaeda H., Sakai T., Asao T., Himeno K., Good R.A., Katunuma N. Lysosomal cathepsin B plays an important role in antigen processing, while cathepsin D is involved in degradation of the invariant chain in ovalbumin-immunized mice. Immunology, 2000, Vol. 100, no. 1, pp. 13-20.